SESSIONE TUMORI GENITOURINARI:
NUOVI DATI
Dott. Antonio Rozzi
Oncologia INI Grottaferrata
Overview
Prostate Cancer
• LBA31 STAMPEDE: Abiraterone or Docetaxel –directly randomised data
Renal Cell Carcinoma
• LBA5 CheckMate214: Phase III Nivolumab+
Ipilimumab vs Sunitinibfor clear cell mRCC
Bladder Cancer
• LBA4 RANGE: Phase III Docetaxel +/-
Ramucirumab in platinum-refractory urothelial cancer
Newly Diagnosed CS Metastatic Prostate Cancer
LBA31 STAMPEDE: Abi or Doc – directly randomised data -No difference in OSS, SSE for ADT+Abi vs ADT+Doc
- Different mechanism of action , side effect profile, treatment duration (18 wks Doc vc until PD for Abi), cost-
effectiveness ratio, …
Renal Cell Carcinoma